Christophe Dooms

机构：KU Leuven · ORCID：0000-0001-7324-7977

发表论文 320 篇 · 总被引 12103 次 · h-index 52

代表论文

• Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial (2024 · The Lancet · 被引 278)
• Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer (2025 · Nature Medicine · 被引 39)
• Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation (2024 · Lung Cancer · 被引 18)
• OA01.03 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC (2024 · Journal of Thoracic Oncology · 被引 12)
• A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer (2024 · Lung Cancer · 被引 11)
• World Association for Bronchology and Interventional Pulmonology ( WABIP ) Guidelines on Airway Stenting for Benign Central Airway Obstruction (2025 · Respirology · 被引 8)